Biology Reference
In-Depth Information
and accurately in one LC MRM-MS run has
become a reality. Even though there are many
hurdles, including assay sensitivity and speci-
for discovery of potential bladder cancer biomarkers.
J Proteomics 2012;
45.
9. Huttenhain R, Soste M, Selevsek N, et al. Reproducible
quanti
75
(12):3529
e
cation of cancer-associated proteins in body
ficity, that still need to be improved and solved,
as already discussed in this chapter, the MRM-
MS-based targeted approach has become a major
step in making proteomics a contributor to
personalized medicine.
fluids using targeted proteomics. Sci Transl Med 2012;
4
:
94.
10. Woolf E, Haddix HM, Matuszewski B. Determination
of an in vivo metabolite of a human immunode
142
e
ciency
virus protease-inhibitor in human plasma by high-
performance liquid chromatography with tandem mass
spectrometry. J Chromatogr A 1997;
9.
11. Schupke H, Hempel R, Eckardt R, Kronbach T. Identi-
762
(1-2):311
e
Acknowledgments
This project has been funded in whole or in part with federal
funds from the National Cancer Institute, National Institutes
of Health, under Contract HHSN261200800001E. The content
of this publication does not necessarily re
fication of talinolol metabolites in urine of man, dog,
rat and mouse after oral administration by high-
performance liquid chromatography-thermospray tan-
dem mass spectrometry. JMassSpectrom1996;
31
(12):
81.
12. Meng Z, Veenstra TD. Targeted mass spectrometry
approaches for proteinbiomarker veri
1371
e
ect the views or
policies of the Department of Health and Human Services,
nor does mention of trade names, commercial products, or
organizations imply endorsement by the United States
Government.
cation. JProteomics
9.
13. Fusaro VA, Mani DR, Mesirov JP, Carr SA. Prediction
of high-responding peptides for targeted protein assays
by mass spectrometry. Nat Biotechnol 2009;
2011;
74
(12):2650
e
27
8.
14. Picotti P, Rinner O, Stallmach R, et al. High-throughput
generation of selected reaction-monitoring assays for
proteins and proteomes. Nat Methods 2010;
(2):190
e
References
1. Anderson NL. The clinical plasma proteome: a survey
of clinical assays for proteins in plasma and serum. Clin
Chem 2010;
7
6.
15. Deribe YL, Pawson T, Dikic I. Post-translational modi-
(1):43
e
85.
2. Rifai N, Gillette MA, Carr SA. Protein biomarker
discovery and validation: the long and uncertain path
to clinical utility. Nat Biotechnol 2006;
56
(2):177
fications in signal integration. Nat Struct Mol Biol 2010;
17
e
72.
16. Minguez P, Parca L, Diella F, et al. Deciphering a global
network of functionally associated post-translational
modi
(6):666
e
83.
3. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site
assessment of the precision and reproducibility of
multiple reaction monitoring-based measurements of
proteins in plasma. Nat Biotechnol 2009;
24
(8):971
e
:599.
17. Braithwaite SP, Stock JB, Mouradian MM.
cations. Mol Syst Biol 2012;
8
-synuclein
phosphorylation as a therapeutic target in Parkinson
a
'
s
41.
4. Kuzyk MA, Smith D, Yang J, et al. Multiple reaction
monitoring-based, multiplexed, absolute quantitation
of 45 proteins in human plasma. Mol Cell Proteomics
2009;
27
(7):633
e
disease. Rev Neurosci 2012;
23
(2):191
8.
e
18.
Jaros JA, Martins-de-Souza D, Rahmoune H, et al.
Protein phosphorylation patterns in serum from schizo-
phrenia patients and healthy controls. J Proteomics 2012;
76
77.
5. Addona TA, Shi X, Keshishian H, et al. A pipeline that
integrates the discovery and veri
8
(8):1860
e
(Spec No):43
e
19. Klammer M, Kaminski M, Zedler A, et al. Phospho-
signature predicts dasatinib response in non-small cell
lung cancer. Mol Cell Proteomics 2012;
cation of plasma
protein biomarkers
reveals
candidate markers
for
43.
6. Whiteaker JR, Lin C, Kennedy J, et al. A targeted
proteomics-based pipeline for veri
cardiovascular disease. Nat Biotechnol 2011;
29
(7):635
e
11
(9):651
68.
e
20. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of
prostate-speci
cation of bio-
markers in plasma. Nat Biotechnol 2011;
29
(7):625
34.
e
c antigen in serum as a screening test for
prostate cancer. N Engl J Med 1991;
7. Drabovich AP, Jarvi K, Diamandis EP. Veri
fication of
male infertility biomarkers in seminal plasma by
multiplex selected reaction monitoring assay. Mol Cell
Proteomics 2011;
61.
21. Elliott P, Chambers JC, Zhang W, et al. Genetic loci
associated with C-reactive protein levels and risk of
coronary heart disease. JAMA 2009;
324
(17):1156
e
:M110.004127.
8. Chen YT, Chen HW, Domanski D, et al. Multiplexed
quanti
10
302
48.
22. Mahmoud FA, Rivera NI. The role of C-reactive protein
as a prognostic indicator in advanced cancer. Curr
Oncol Rep 2002;
(1):37
e
cation of 63 proteins in human urine by
multiple reaction monitoring-based mass spectrometry
4
(3):250
5.
e
Search WWH ::
Custom Search